Literature DB >> 18775113

Hypertension management in patients with chronic kidney disease.

Biff F Palmer1.   

Abstract

Hypertension is one of the major risk factors for the development and progression of chronic kidney disease. The loss of renal function leads to impaired renal autoregulation and renders the kidney vulnerable to the damaging effects of uncontrolled hypertension. Mounting evidence indicates that angiotensin-converting enzyme inhibitors and angiotensin receptor blockers slow the progression of chronic kidney disease through effects beyond lowering blood pressure. Studies are needed to determine whether high doses of the single agent or combination therapy is most effective in providing renal protection. Urinary protein excretion is a useful tool for monitoring and titrating therapy to maximize renal protection. Changes in the serum creatinine concentration and hyperkalemia are complications of antihypertensive therapy in patients with chronic kidney disease that can be successfully managed to allow continued use of renin-angiotensin blockade.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18775113     DOI: 10.1007/s11906-008-0069-z

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  40 in total

1.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

2.  Remission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the Captopril Study.

Authors:  W A Wilmer; L A Hebert; E J Lewis; R D Rohde; F Whittier; D Cattran; A S Levey; J B Lewis; S Spitalewitz; S Blumenthal; R P Bain
Journal:  Am J Kidney Dis       Date:  1999-08       Impact factor: 8.860

Review 3.  The role of ambulatory blood pressure monitoring in chronic and end-stage renal disease.

Authors:  A M Thompson; T G Pickering
Journal:  Kidney Int       Date:  2006-07-19       Impact factor: 10.612

Review 4.  An in-depth review of the evidence linking dietary salt intake and progression of chronic kidney disease.

Authors:  Charlotte Jones-Burton; Shiraz I Mishra; Jeffrey C Fink; Jeanine Brown; Weyinshet Gossa; George L Bakris; Matthew R Weir
Journal:  Am J Nephrol       Date:  2006-06-09       Impact factor: 3.754

5.  Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial.

Authors:  Naoyuki Nakao; Ashio Yoshimura; Hiroyuki Morita; Masyuki Takada; Tsuguo Kayano; Terukuni Ideura
Journal:  Lancet       Date:  2003-01-11       Impact factor: 79.321

6.  Lower blood pressure and risk of recurrent stroke in patients with chronic kidney disease: PROGRESS trial.

Authors:  T Ninomiya; V Perkovic; M Gallagher; M Jardine; A Cass; H Arima; C Anderson; B Neal; M Woodward; T Omae; S MacMahon; J Chalmers
Journal:  Kidney Int       Date:  2008-02-13       Impact factor: 10.612

7.  The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide.

Authors:  H Buter; M H Hemmelder; G Navis; P E de Jong; D de Zeeuw
Journal:  Nephrol Dial Transplant       Date:  1998-07       Impact factor: 5.992

8.  Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes.

Authors:  F Persson; P Rossing; K J Schjoedt; T Juhl; L Tarnow; C D A Stehouwer; C Schalkwijk; F Boomsma; E Frandsen; H-H Parving
Journal:  Kidney Int       Date:  2008-03-12       Impact factor: 10.612

Review 9.  Do agents that block the RAS truly offer renoprotective effects in early stage, nonproteinuric nephropathy?

Authors:  Radica Alicic; Katherine R Tuttle
Journal:  Curr Hypertens Rep       Date:  2007-11       Impact factor: 5.369

Review 10.  Current concepts: renin inhibition in the treatment of hypertension.

Authors:  Alan H Gradman; Rekha Pinto; Rishi Kad
Journal:  Curr Opin Pharmacol       Date:  2008-03-04       Impact factor: 5.547

View more
  4 in total

Review 1.  Chronotherapy for Hypertension.

Authors:  N P Bowles; S S Thosar; M X Herzig; S A Shea
Journal:  Curr Hypertens Rep       Date:  2018-09-28       Impact factor: 5.369

Review 2.  Management of hypertension in chronic kidney disease.

Authors:  Raymond R Townsend; Sandra J Taler
Journal:  Nat Rev Nephrol       Date:  2015-07-28       Impact factor: 28.314

3.  Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial.

Authors:  Bertram Pitt; Stefan D Anker; David A Bushinsky; Dalane W Kitzman; Faiez Zannad; I-Zu Huang
Journal:  Eur Heart J       Date:  2011-01-05       Impact factor: 29.983

4.  PET-CT and RNA sequencing reveal novel targets for acupuncture-induced lowering of blood pressure in spontaneously hypertensive rats.

Authors:  Jing Li; Chong Peng; Dongjian Lai; Yajing Fang; Daihong Luo; Zunming Zhou; Chenyun Li; Xinsheng Lai
Journal:  Sci Rep       Date:  2021-05-26       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.